Cookie Policy

This site uses cookies to store information on your computer.

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

CENTURY II Trial highlights

01/10/2015 -  

Multicentre, intercontinental study - 58 sites in 13 countries across Europe, Japan, and South Korea - Primary endpoint: Freedom from TLF at 9 months - Secondary endpoint: rate of TVF; patient-oriented composite endpoint; rate of TLR, TVR, ST, cardiac death, MI; composite of cardiac death and MI; rate of bleeding and vascular complications - Clinical follow-up up to 5 years

Study design and key features

 


 "Xience" is a product and trademark of the Abbott Group of Companies

Ultimaster was non-inferior to Xience in terms of the primary endpoint: freedom from TLF at 9 months

 

Saito S et al. Eur Heart J 2014;35:2021–31.


 

CENTURY II included pre-specified assessment of complex subgroups

 


 

CENTURY II Bifurcation lesions. Target Lesion Failure at 24 months

 

B. Merkely et al. Treatment of bifurcation lesions with a thin-strut DES with bioresorbable polymer – clinical outcomes of the CENTURY II trial. Presented at EuroPCR 2015.
Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2015 Aug 13. doi: 10.1002/ccd.26150.


 

CENTURY II Bifurcation lesions. Clinical outcomes at 24 months

 

B. Merkely et al. Treatment of bifurcation lesions with a thin-strut DES with bioresorbable polymer – clinical outcomes of the CENTURY II trial. Presented at EuroPCR 2015.
Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2015 Aug 13. doi: 10.1002/ccd.26150.